Publication:
Long-term results of Gamma Knife radiosurgery for facial nerve schwannomas

dc.contributor.coauthorŞirin, Alperen
dc.contributor.coauthorYılmaz, Meltem
dc.contributor.coauthorŞengöz, Meriç
dc.contributor.departmentSchool of Medicine
dc.contributor.kuauthorAkyoldaş, Göktuğ
dc.contributor.kuauthorPeker, Selçuk
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.date.accessioned2024-11-10T00:06:06Z
dc.date.issued2020
dc.description.abstractObjective: Long-term outcomes of eleven cases of facial nerve schwannoma were evaluated and the related literature was reviewed to determine the efficacy of Gamma Knife radiosurgery for treating patients with facial nerve schwannoma. Methods: Eleven patients with facial nerve schwannoma (7 women and 4 men; mean age, 44.2 years; range, 19-73 years) underwent Gamma Knife radiosurgery. The most common symptoms were facial palsy (n = 10) and hearing loss (n = 7). Five patients presented with headache. Two patients had undergone prior resection. The patients' clinical and radiographic data were evaluated retrospectively. Results: For the 11 cases of facial nerve schwannoma, mean tumor volume was 3.1 cm(3) (range, 0.4-7.4 cm(3)) and the mean marginal dose applied was 11.9 Gy (range, 11-13 Gy). The mean follow-up period was 84.3 months (range, 66-117 months). Tumor control was achieved in all patients. At the time of writing, four patients experienced tumor volume regression and the other seven were in stable condition. During follow-up, nine patients experienced no change in their facial function, two experienced deteriorated facial function, and none developed new facial palsy. Ten patients who had serviceable hearing prior to Gamma Knife radiosurgery retained their hearing. Conclusions: Gamma Knife radiosurgery achieves excellent results with respect to tumor control for 7 years on average. In addition, Gamma Knife radiosurgery provides good results in facial nerve and hearing function at long term. Our series demonstrates that Gamma Knife radiosurgery is an effective and safe treatment for patients with either primary or residual facial nerve schwannoma.
dc.description.indexedbyWOS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.issue12
dc.description.openaccessNO
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuN/A
dc.description.volume42
dc.identifier.doi10.1080/01616412.2020.1796379
dc.identifier.eissn1743-1328
dc.identifier.issn0161-6412
dc.identifier.quartileQ3
dc.identifier.scopus2-s2.0-85088461431
dc.identifier.urihttps://doi.org/10.1080/01616412.2020.1796379
dc.identifier.urihttps://hdl.handle.net/20.500.14288/16556
dc.identifier.wos551604600001
dc.keywordsFacial nerve schwannoma
dc.keywordsGamma Knife
dc.keywordsOncology
dc.keywordsStereotactic radiosurgery
dc.keywordsFractionated stereotactic radiotherapy
dc.keywordsCase series
dc.keywordsManagement
dc.keywordsOutcomes
dc.keywordsSurgery
dc.keywordsNeuromas
dc.language.isoeng
dc.publisherTaylor & Francis
dc.relation.ispartofNeurological Research
dc.subjectClinical neurology
dc.subjectNeurosciences
dc.titleLong-term results of Gamma Knife radiosurgery for facial nerve schwannomas
dc.typeJournal Article
dspace.entity.typePublication
local.contributor.kuauthorAkyoldaş, Göktuğ
local.contributor.kuauthorPeker, Selçuk
local.publication.orgunit1SCHOOL OF MEDICINE
local.publication.orgunit2School of Medicine
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublication.latestForDiscoveryd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublication.latestForDiscovery17f2dc8e-6e54-4fa8-b5e0-d6415123a93e

Files